Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Qian Geng, Hua Shen, Wenyu Zhu, Yingzhi Lu, Mengjie Wang, Hua Jiang & Dongqing Li. (2020) Safety and Efficacy of Low-Dosage Apatinib Monotherapy in Advanced Lung Squamous-Cell Carcinoma: A Prospective Cohort Study. OncoTargets and Therapy 13, pages 11529-11535.
Read now
Read now
Hongchao Zhen, Guangxin Li, Pengfei Zhao, Ying Zhang, Jing Wang, Junxian Yu & Bangwei Cao. (2020) Raltitrexed Enhances the Antitumor Effect of Apatinib in Human Esophageal Squamous Carcinoma Cells via Akt and Erk Pathways. OncoTargets and Therapy 13, pages 12325-12339.
Read now
Read now
Guohui Liu, Yanbo Wang, Chunbo Wang, Yunlong He & Mingyan E. (2020) Clinical efficacy and safety of apatinib as maintenance treatment in patients with advanced esophageal squamous cell carcinoma. Expert Review of Clinical Pharmacology 13:12, pages 1423-1430.
Read now
Read now
A Spagnuolo, G Palazzolo, C Sementa & C Gridelli. (2020) Vascular endothelial growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small cell lung cancer. Expert Opinion on Pharmacotherapy 21:4, pages 491-506.
Read now
Read now
Lan Shao, Wenxian Wang, Zhengbo Song & Yiping Zhang. (2019) The efficacy and safety of anlotinib treatment for advanced lung cancer. OncoTargets and Therapy 12, pages 6549-6554.
Read now
Read now
Shen-Cun Fang, Wen Huang, Ying-Ming Zhang, Hai-Tao Zhang & Wei-Ping Xie. (2019) Hypertension as a predictive biomarker in patients with advanced non-small-cell lung cancer treated with apatinib. OncoTargets and Therapy 12, pages 985-992.
Read now
Read now
Deze Zhao, Helei Hou & Xiaochun Zhang. (2018) Progress in the treatment of solid tumors with apatinib: a systematic review. OncoTargets and Therapy 11, pages 4137-4147.
Read now
Read now
Xiaofen Li, Xia Li, Xuefeng Fang & Ying Yuan. (2018) Long-term progression-free survival of third-line apatinib in lung squamous cell carcinoma. OncoTargets and Therapy 11, pages 4047-4050.
Read now
Read now
Fengying Wu, Shijia Zhang, Guanghui Gao, Jing Zhao, Shengxiang Ren & Caicun Zhou. (2018) Successful treatment using apatinib with or without docetaxel in heavily pretreated advanced non-squamous non-small cell lung cancer: A case report and literature review. Cancer Biology & Therapy 19:3, pages 141-144.
Read now
Read now
Da-xiong Zeng, Chang-guo Wang, Jian-an Huang & Jun-hong Jiang. (2017) Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation. OncoTargets and Therapy 10, pages 4269-4272.
Read now
Read now
Jianqiang Li & Lifen Wang. (2017) Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma. OncoTargets and Therapy 10, pages 3965-3969.
Read now
Read now
Jinling Bi, Haiyuan Liu & Yong Huang. (2017) The effect of apatinib in the treatment of metastatic renal cell carcinoma: a case report and review of the literature. International Medical Case Reports Journal 10, pages 223-227.
Read now
Read now
Articles from other publishers (33)
Wenxian Wang, Lan Shao, Yibing Xu, Zhengbo Song, Guangyuan Lou, Yiping Zhang & Ming Chen. (2022) Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study. BMC Pulmonary Medicine 22:1.
Crossref
Crossref
Jijin Wang, Di Huang, Wenjing Yang, Qingxu Song, Yibin Jia, Pengxiang Chen & Yufeng Cheng. (2022) The efficacy and safety of Apatinib in the treatment of advanced non-small cell lung cancer: A retrospective trial. Frontiers in Oncology 12.
Crossref
Crossref
Cheng Chen, Xiaoting Duan, Yanfeng Shen & Guiying Li. (2022) The clinical efficacy and safety of TACE combined with apatinib for advanced hepatocellular carcinoma: A propensity score matching analysis. Indian Journal of Cancer 0:0, pages 0.
Crossref
Crossref
Congcong Ren, Jing Zhao, Lin Kang, Yan Di, Gang Qiu & Qingxue Wang. (2021) Successful treatment of radiotherapy and apatinib in patient with mediastinal mixed non-seminomatous germ cell tumor. Medicine 100:43, pages e27617.
Crossref
Crossref
Bin Wei, Yuanyuan Wang, Jiawei Wang, Xiaomin Cai, Lingyan Xu, Jingjing Wu, Ying Wang, Wen Liu, Yanhong Gu, Wenjie Guo & Qiang Xu. (2020) Apatinib suppresses tumor progression and enhances cisplatin sensitivity in esophageal cancer via the Akt/β-catenin pathway. Cancer Cell International 20:1.
Crossref
Crossref
Wei Li, Chengguan Feng, Weihong Di, Shanwen Hong, Hui Chen, Mubashir Ejaz, Yang Yang & Tian-rui Xu. (2020) Clinical use of vascular endothelial growth factor receptor inhibitors for the treatment of renal cell carcinoma. European Journal of Medicinal Chemistry 200, pages 112482.
Crossref
Crossref
Fen Wang, Xia Yuan, Jun Jia, Xiaoxia Bi, Zeqiang Zhou, Qiming Zhou, Xia Li, Changguo Luo, Minghui Deng, Liangjie Yi, Yong Li, Jianxin Lu, Wenzhi Su, Hanbin Chen, Yu Zhu & Shubin Wang. (2020) Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study. Scientific Reports 10:1.
Crossref
Crossref
Jianxia Wen, Tao Yang, Jian Wang, Xiao Ma, Yuling Tong & Yanling Zhao. (2020) Kanglaite Injection Combined with Chemotherapy versus Chemotherapy Alone for the Improvement of Clinical Efficacy and Immune Function in Patients with Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Evidence-Based Complementary and Alternative Medicine 2020, pages 1-15.
Crossref
Crossref
Jian Li, Xiwen Tong & Hongtao Li. (2020) Efficacy and safety of apatinib monotherapy in elderly patients with advanced metastatic non-small cell lung cancer. Indian Journal of Cancer 57:1, pages 13.
Crossref
Crossref
Jianmiao Liang, Weiguang Gu, Jun Jin, Hua Zhang, Zecheng Chen, Yicong Tang, Shunda Zhang, Shuang Yang, Yanming Deng & Weineng Feng. (2020) Efficacy and safety of apatinib as third- or further-line therapy for patients with advanced NSCLC: a retrospective study. Therapeutic Advances in Medical Oncology 12, pages 175883592096847.
Crossref
Crossref
Jian-Chun Duan, Zhi-Jie Wang, Lin Lin, Jun-Ling Li, Yan Wang, Hua Bai, Xing-Sheng Hu, Yu-Tao Liu, Xue-Zhi Hao, Hong-Yu Wang, Rui Wan, Xin Wang & Jie Wang. (2019) Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial. Investigational New Drugs 37:4, pages 731-737.
Crossref
Crossref
Jing Tang, Xu Yong Li, Jing Bo Liang, De Wu, Li Peng & Xiaobing Li. (2019) Apatinib Plus Chemotherapy Shows Clinical Activity in Advanced NSCLC: A Retrospective Study. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 27:6, pages 635-641.
Crossref
Crossref
Qian Jiang, Ning-Ling Zhang, Dai-Yuan Ma, Bang-Xian Tan, Xin Hu & Xiang-Dong Fang. (2019) Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC. Medicine 98:26, pages e16065.
Crossref
Crossref
Zhichao Tian, Zhiyuan Gu, Xin Wang, Zhiyong Liu, Weitao Yao, Jiaqiang Wang, Peng Zhang, Qiqing Cai & Hong Ge. (2019) Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy. Medicine 98:19, pages e15650.
Crossref
Crossref
Da-xiong Zeng, Wei Lei, Chang-guo Wang, Jian-an Huang & Jun-hong Jiang. (2018) Low dosage of apatinib monotherapy as rescue treatment in advanced lung squamous cell carcinoma. Cancer Chemotherapy and Pharmacology 83:3, pages 439-442.
Crossref
Crossref
Jin Liu, Yulong Zheng & Nong Xu. (2019) Low dose of apatinib in treating chemotherapy and EGFR-TKI refractory non-small cell lung cancer. Medicine 98:5, pages e14328.
Crossref
Crossref
Jianxin Chen, Junhui Wang & Qian Miao. (2019) Careful dose modification of apatinib as third or further-line treatment in advanced gastric cancer patients with poor performance status. Medicine 98:45, pages e17890.
Crossref
Crossref
Jiao Leng, Dai-Rong Li, Lu-Mi Huang, Xiao-Hui Ji & Dong-Lin Wang. (2019) Apatinib is effective as third-line and more treatment of advanced metastatic non-small-cell lung cancer. Medicine 98:36, pages e16967.
Crossref
Crossref
Jun Jin, Jiahao Du & Yanwei Wu. (2019) Apatinib monotherapy for advanced VEGFR-2-negative nasopharyngeal carcinoma. Medicine 98:1, pages e13491.
Crossref
Crossref
Lijun Hu, Fei Sun, Zhiqiang Sun, Xinchu Ni, Jian Wang, Jianlin Wang, Mengyun Zhou, Yue Feng, Ze Kong, Qiu Hua & Jingping Yu. (2018) Apatinib enhances the radiosensitivity of the esophageal cancer cell line KYSE‑150 by inducing apoptosis and cell cycle redistribution. Oncology Letters.
Crossref
Crossref
Di Wu, Li Liang, Ligong Nie, Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, Xiaoling Chen, Jindi Han, Xiangjuan Ma, Guangming Tian, Sen Han, Jieran Long, Yang Wang, Ziran Zhang, Tao Xin & Jian Fang. (2018) Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC. Asia-Pacific Journal of Clinical Oncology 14:6, pages 446-452.
Crossref
Crossref
Zedong Du, Yanxin Yu, Dajun Wu, Guangyu Zhang, Yang Wang, Liang He & RongQin Meng. (2018) Apatinib for salvage treatment of advanced malignant pleural mesothelioma. Medicine 97:45, pages e13105.
Crossref
Crossref
Fengying Wu, Shijia Zhang, Anwen Xiong, Guanghui Gao, Wei Li, Weijing Cai, Chunxia Su, Xiaoxia Chen, Fei Zhou, Jing Zhao, Shengxiang Ren & Caicun Zhou. (2018) A Phase II Clinical Trial of Apatinib in Pretreated Advanced Non-squamous Non–small-cell Lung Cancer. Clinical Lung Cancer 19:6, pages e831-e842.
Crossref
Crossref
Zui Liu, Wei Ou, Ning Li & Si-Yu Wang. (2018) Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy. Thoracic Cancer 9:10, pages 1285-1290.
Crossref
Crossref
Jie-Tao Ma, Jing Sun, Li Sun, Shu-Ling Zhang, Le-Tian Huang & Cheng-Bo Han. (2018) Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs. Medicine 97:35, pages e12083.
Crossref
Crossref
Dexiang Yang, Ranran Dai, Qi Zhang & Ping Fang. (2018) Apatinib for heavily treated patients with non-small cell lung cancer: Report of a case series and literature review. Saudi Journal of Biological Sciences 25:5, pages 888-894.
Crossref
Crossref
Jianping Xu, Xiaoyan Liu, Sheng Yang, Xiangru Zhang & Yuankai Shi. (2018) Clinical response to apatinib monotherapy in advanced non-small cell lung cancer. Asia-Pacific Journal of Clinical Oncology 14:3, pages 264-269.
Crossref
Crossref
Xiaojin Li, Anjian Xu, Huihui Li, Bei Zhang, Bangwei Cao & Jian Huang. (2018) Novel role of apatinib as a multi-target RTK inhibitor in the direct suppression of hepatocellular carcinoma cells. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1864:5, pages 1693-1701.
Crossref
Crossref
Lesley J. Scott. (2018) Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers. Drugs 78:7, pages 747-758.
Crossref
Crossref
Miaomiao Gou, Haiyan Si, Yong Zhang, Niansong Qian, Zhikuan Wang, Weiwei Shi & Guanghai Dai. (2018) Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study. Scientific Reports 8:1.
Crossref
Crossref
Yong Zhang, Miaomiao Gou, Chun Han, Juan Li, Lijie Wang, Qian Qiao, Yi Hu, Li Bai & Zhefeng Liu. (2018) Efficacy and safety of apatinib as second-line therapy for advanced gastric cancer. Anti-Cancer Drugs 29:2, pages 184-189.
Crossref
Crossref
Shencun Fang, Meiling Zhang, Guihong Wei & Kai-Hua Lu. (2017) Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR. Oncotarget 9:6, pages 7175-7181.
Crossref
Crossref
Yinlong Kong, Lin Sun, Zhenyu Hou, Yongqiang Zhang, Ping Chen, Yunlong Cui, Xiaolin Zhu, Tianqiang Song, Qiang Li, Huikai Li, Ti Zhang & Lunxiu Qin. (2017) Apatinib is effective for treatment of advanced hepatocellular carcinoma. Oncotarget 8:62, pages 105596-105605.
Crossref
Crossref